Press release
Investigation announced for Long-Term Investors in shares of Verve Therapeutics, Inc. (NASDAQ: VERV) over potential Wrongdoing
An investigation on behalf of current long term investors in Verve Therapeutics, Inc. (NASDAQ: VERV) shares.
Investors who are current long term investors in Verve Therapeutics, Inc. (NASDAQ: VERV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: VERV stocks follows a lawsuit filed against Verve Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: VERV stocks, concerns whether certain Verve Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose, among other things, that defendants did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial (the "Heart-1 Trial") of VERVE-101 would be halted (VERVE-101 is an investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver to reduce disease-driving low-density lipoprotein cholesterol (LDL-C)), that the defendants overstated the potential benefits of its proprietary lipid nanoparticle (LNP) delivery system, and that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times
Those who purchased shares of Verve Therapeutics, Inc. (NASDAQ: VERV) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Verve Therapeutics, Inc. (NASDAQ: VERV) over potential Wrongdoing here
News-ID: 3940278 • Views: …
More Releases from Shareholders Foundation, Inc.
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for VERV
Comprehensive 2025 Malaria Treatment Market Overview: Trends, Forecasts, and Gro …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Malaria Treatment Market Through 2025?
Over the past few years, there has been a consistent growth in the size of the malaria treatment market. The market, which stands at $1.55 billion in 2024, is projected to expand to $1.61 billion in 2025,…
Malaria Treatment Market Report 2025-2034: Industry Overview, Trends, And Foreca …
The Malaria Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Malaria Treatment Market Size and Its Estimated Growth Rate?
In the last few years, the market size for malaria treatment has consistently expanded. It is projected to increase from $1.55 billion…
Key Trend Reshaping the Vector Control Market in 2025: The VERV Program's Impact …
Which drivers are expected to have the greatest impact on the over the vector control market's growth?
The escalation in cases of diseases transmitted through vectors is set to fuel the growth of the vector control market. Elements such as climate changes and geographical distribution directly contribute to the transmission and proliferation of vector-borne diseases. This surge in prevalence has necessitated the implementation of vector control strategies. These strategies aim to…
Deadline coming up on Oct. 28th in Lawsuit for Investors who lost money with Ver …
A deadline is coming up on October 28, 2024 in the lawsuit filed for certain investors of Verve Therapeutics, Inc. (NASDAQ: VERV) over alleged securities laws violations by Verve Therapeutics, Inc.
Investors who purchased shares of Verve Therapeutics, Inc. (NASDAQ: VERV) have certain options and there are strict and short deadlines running. Deadline: October 28, 2024. Verve Therapeutics, Inc. (NASDAQ: VERV) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Lawsuit Alert: Investors who lost money with shares of Verve Therapeutics, Inc. …
An investor, who purchased shares of Verve Therapeutics, Inc. (NASDAQ: VERV), filed a lawsuit over alleged violations of Federal Securities Laws by Verve Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Verve Therapeutics, Inc. (NASDAQ: VERV) have certain options and for certain investors are short and strict deadlines running. Deadline: October 28, 2024. NASDAQ: VERV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
New Digital Marketing Agency VERV Local Drives Growth for Small Businesses
Image: https://www.getnews.info/wp-content/uploads/2024/05/1716499517.png
Empowering local enterprises through tailored strategies and proven results.
VERV Local is a new digital marketing agency that aims to redefine the way small businesses harness the power of digital marketing for growth and success. Focusing exclusively on serving the needs of small businesses, VERV Local understands the unique challenges and opportunities that arise in this market segment.
Limited resources, including budget constraints and manpower shortages, often force small business owners…
